Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
110 BDS graduates admitted in week one of the launch
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Clinical trial supply company strengthens its presence in the European Union
Subscribe To Our Newsletter & Stay Updated
